News - elvitegravir


Current filters:


Popular Filters

US FDA delays approval of Gilead's elvitegravir and cobicistat for HIV


US antiviral drug specialists Gilead Sciences (Nasdaq: GILD) says it has received Complete Response Letters…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaRegulation

Japan Tobacco files for Japanese approval of elvitegravir


Japan Tobacco (TSE:2914) has filed a New Drug Application for marketing approval of a novel anti-HIV…

Anti-viralsAsia-PacificBiotechnologyelvitegravirGilead SciencesJapan TobaccoPharmaceuticalRegulationTorii Pharma

Batch of clinical trial results for Gilead's elvitegravir, Complera and cobicistat


US biotech firm Gilead Sciences (Nasdaq: GILD), the world's biggest producer of HIV treatments, announced…

Anti-viralsBiotechnologycobicistatCompleraelvitegravirGilead SciencesResearch

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing


US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

Back to top